Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Clinical Cancer Research|2018Cited by 195
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Darko Antić et al.|Blood|2021Cited by 70
Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Ebba Sohlberg et al.|Unknown|2023Cited by 0
Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0
Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0